This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Virios Therapeutics’s 8K filing here.
About Virios Therapeutics
Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
Recommended Stories
- Five stocks we like better than Virios Therapeutics
- Best Stocks Under $5.00
- California Resources Stock Could Be a Huge Long-Term Winner
- How to Invest in Insurance Companies: A Guide
- Observability Wars: Datadog and Dynatrace Vie for Data Dominance
- 3 Warren Buffett Stocks to Buy Now
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
